
News|Articles|December 27, 2024
Top 5 News Articles of 2024
Author(s)MHE Staff
Of the top news articles, Vertex Pharmaceuticals' suzetrigine garnered much attention as it's a promising new class of pain medicine that might offer hope for those struggling with acute pain issues who want to avoid opioids and NSAIDs.
Advertisement
- UnitedHealthcare Adds Deductibles to Medicare Part D for 2025
 UnitedHealthcare is adding deductibles to Part D prescriptions on certain formulary tiers as a result of plan design changes from the Inflation Reduction Act.Read more 
- Cataract Surgery: It Is More Than Just Your Vision That Improves
 Researchers have identified an association between cataract surgery and a lower risk of cognitive decline and dementia.Read more 
- NDA Resubmitted for Dry Eye Treatment Reproxalap
 Dry eye disease affects up to 15% of the U.S. population and is one of the largest markets in the ophthalmology field.Read here 
- mRNA Vaccine Momentum
 The success of mRNA vaccines against COVID-19 has led to a surge of mRNA vaccines being developed for other diseases.Read here 
- A New Class of Medicine for Pain Relief on The Horizon
 Developed by Vertex Pharmaceuticals, suzetrigine is a promising new class of pain medicine that has been gaining attention for its innovative mechanism of action and reported efficacy; suzetrigine might offer hope for those struggling with acute pain issues who want to avoid opioids and NSAIDs.Read here 
Newsletter
Get the latest industry news, event updates, and more from Managed healthcare Executive.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Understanding Hemophilia A and B
2
Nonfactor Therapies for Hemophilia: Current Evidence, Clinical Relevance and Cost Considerations
3
Nonfactor agents for hemophilia prophylaxis: A Q&A with Steven Pipe, M.D.
4
Payers Are Bracing for the Specialty Trend of the Future | AMCP Nexus 2025
5



















































